Avalo Therapeutics (AVTX) Price & Analysis

Compare

1,028 Followers

AVTX Stock Chart & Stats

$15.35

-$0.55(-7.32%)

At close: Jan 08 4:00 PM EST

$15.35

-$0.55(-7.32%)

Day’s Range― - ―

52-Week Range$3.39 - $16.00

Previous CloseN/A

Volume10.82K

Average Volume (3M)389.85K

Market Cap

$184.13M

Enterprise Value-$56.56M

Total Cash (Recent Filing)$113.28M

Total Debt (Recent Filing)$2.68M

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Nov 06, 2025

EPS Estimate

-1.66

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.92

Shares Outstanding13,152,356

10 Day Avg. Volume302,611

30 Day Avg. Volume389,845

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.45

Price to Sales (P/S)136.95

P/FCF Ratio-1.23

Enterprise Value/Market Cap-0.31

Enterprise Value/Revenue-128.26

Enterprise Value/Gross Profit-60.56

Enterprise Value/Ebitda0.92

Forecast

1Y Price Target

$33.97

Price Target Upside121.30% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Financial StabilityAvalo's cash position of $113.3M is expected to fund operations into 2028, extending the runway through key value inflection points, such as Phase 2 data for AVTX-009 in mid-2026.

Market PotentialThe large, underpenetrated HS market with high-growth potential offers room for multiple advanced therapies, including AVTX-009, to be commercially successful.

Product AdvantageAVTX-009 offers asymmetric upside if it can deliver due to its once-monthly dosing advantage and the potential to match or exceed the efficacy of current treatments.

Bears Say

Clinical Development RisksRisks include delays in clinical development, negative clinical data, failure to achieve approval, slower-than-anticipated commercial uptake, and possible dilution risk.

Financial PerformanceAvalo recorded a 2Q25 net loss of $1.92 per share, which was higher than the estimated net loss of $1.23 per share.

Avalo Therapeutics News

Avalo Therapeutics management to meet with Piper Sandler

Meetings to be held in Boston on October 14 and in New York on October 15 hosted by...

3d ago

AVTX

Avalo Therapeutics appoints Boyd as CBO, Ivanowicz as SVP, Human Resources

Avalo Therapeutics (AVTX) announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been...

17d ago

AVTX

Avalo Therapeutics appoints Kevin Lind to board of directors

Avalo Therapeutics (AVTX) announced the appointment of Kevin Lind to its Board of Directors. He most recently served...

26d ago

AVTX

Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation

Avalo Therapeutics ( ($AVTX) ) has shared an update. On October 10, 2025, Avalo Therapeutics released an updated...

8d ago

AVTX

Avalo Therapeutics Strengthens Leadership with Key Appointments

An announcement from Avalo Therapeutics ( ($AVTX) ) is now available. On October 1, 2025, Avalo Therapeutics announced...

17d ago

AVTX

Avalo Therapeutics Appoints Kevin Lind to Board

Avalo Therapeutics ( ($AVTX) ) has provided an update. On September 16, 2025, Avalo Therapeutics announced the appointment...

26d ago

AVTX

Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avalo Therapeutics (AVTX) to $25 from $15 and keeps a...

1M ago

ABBV

AVTX

Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data

Oppenheimer recommends investors to be buyers of Avalo Therapeutics (AVTX) in anticipation of the presentation of lutikizumab’s open-label...

1M ago

AVTX

3 Best Stocks to Buy Now, 9/12/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

AVTX

ENVX

3 Best Stocks to Buy Now, 9/5/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

AVTX

Buy Rating for Avalo Therapeutics Driven by Promising AVTX-009 Development and Market Potential

Stacy Ku, an analyst from TD Cowen, has initiated a new Buy rating on Avalo Therapeutics (AVTX). Stacy...

1M ago

AVTX

Avalo Therapeutics initiated with a Buy at TD Cowen

TD Cowen analyst Stacy Ku initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and no price...

1M ago

AVTX

Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Avalo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Avalo Therapeutics (AVTX) with an Overweight rating and no price...

2M ago

AVTX

AVTX FAQ

What was Avalo Therapeutics’s price range in the past 12 months?

Avalo Therapeutics lowest stock price was $3.39 and its highest was $16.00 in the past 12 months.

What is Avalo Therapeutics’s market cap?

Avalo Therapeutics’s market cap is $184.13M.

When is Avalo Therapeutics’s upcoming earnings report date?

Avalo Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.

How were Avalo Therapeutics’s earnings last quarter?

Avalo Therapeutics released its earnings results on Aug 07, 2025. The company reported -$1.92 earnings per share for the quarter, missing the consensus estimate of -$1.402 by -$0.518.

Is Avalo Therapeutics overvalued?

According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avalo Therapeutics pay dividends?

Avalo Therapeutics does not currently pay dividends.

What is Avalo Therapeutics’s EPS estimate?

Avalo Therapeutics’s EPS estimate is -1.66.

How many shares outstanding does Avalo Therapeutics have?

Avalo Therapeutics has 13,152,356 shares outstanding.

What happened to Avalo Therapeutics’s price movement after its last earnings report?

Avalo Therapeutics reported an EPS of -$1.92 in its last earnings report, missing expectations of -$1.402. Following the earnings report the stock price went up 0.481%.

Which hedge fund is a major shareholder of Avalo Therapeutics?

Currently, no hedge funds are holding shares in AVTX

Avalo Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-90.25%

Trailing 12-Months

Asset Growth

16.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avalo Therapeutics

Avalo Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare and ultra-rare diseases. The company targets conditions with significant unmet medical needs, leveraging its proprietary platform to discover and develop novel treatments that improve patient outcomes. Avalo's core pipeline includes a range of product candidates designed to address genetic disorders and other serious health conditions, aiming to provide effective solutions for patients who have limited treatment options.

Avalo Therapeutics (AVTX) Earnings & Revenues

Historic Earnings Reports

AVTX Stock 12 Month Forecast

Average Price Target

$33.97

▲(121.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","14.5":"$14.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.822663,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.5,26,37.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.96,15.655384615384616,18.35076923076923,21.04615384615385,23.74153846153846,26.43692307692308,29.132307692307695,31.82769230769231,34.52307692307693,37.21846153846154,39.91384615384615,42.60923076923077,45.30461538461539,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.96,14.576153846153847,16.192307692307693,17.80846153846154,19.424615384615386,21.04076923076923,22.65692307692308,24.27307692307692,25.88923076923077,27.505384615384614,29.12153846153846,30.737692307692306,32.35384615384615,{"y":33.97,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.96,13.487897153846154,14.015794307692309,14.543691461538462,15.071588615384616,15.59948576923077,16.127382923076922,16.655280076923077,17.183177230769232,17.711074384615383,18.238971538461538,18.76686869230769,19.294765846153844,{"y":19.822663,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >